ProShares Ultra NASDAQ Biotechnology

BIB

Market cap $88.7M

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

BIB seeks 2× the daily return of the Nasdaq Biotechnology Index, amplifying both gains and losses through leverage. A higher expense ratio reflects leverage costs and management fees; 24 bps difference largely from borrowing and rebate adjustments. Designed for tactical investors, contrasting with MPT's long-term strategic approach assuming market efficiency.

President Donald Trump delivered the pharmaceutical industry another blow this week, threatening 100% tariffs on some companies.

Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month, making good on months of threats.

President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon."

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?

All eyes will remain on big tech this week with Microsoft, Amazon, Meta, and Apple set to report for Q2. Outlier earnings this week include - McDonald's & Boeing. During this second peak week of the Q2 season, nearly 2,500 companies are set to report.

Some of the market's favorite biotech stocks have created immense wealth, as in the recent weight-loss drug stock boom.  On May 26, Viking Therapeutics (NASDAQ: VKTX ) was trading around $20.25.

With new innovation, high demand for better treatment, pharmaceutical companies strengthening pipelines and a resurgence of mergers and acquisitions, biotech stocks could offer some of the most explosive opportunities of the year. “What's more, big pharmaceutical companies with sizable piles of cash and the need to address patent expirations on some top-selling products later this decade will be hunting for companies with innovative drugs in development,” says Morningstar.com.